BenzingaAugust 13, 2026 at 8:33 AM NY22 days ago

Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $64

Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $58 to $64.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story